Cas no 1719-79-5 (20α-Dihydrocortisol)
20α-Dihydrocortisol Chemical and Physical Properties
Names and Identifiers
-
- Pregn-4-en-3-one,11,17,20,21-tetrahydroxy-, (11b,20S)-
- 20-ALPHA-DIHYDROCORTISOL
- 20-α-DIHYDROCORTISOL
- 4-PREGNEN-11B,17A,20A,21-TETROL-3-ONE
- 11B,17ALPHA,20ALPHA,21-Tetrahydroxy-4-pregnen-3-one
- 20alpha-hydroxycortisol
- 4-PREGNEN-11BETA,17ALPHA,20ALPHA,21-TETROL-3-ONE
- 4-pregnene-11B,17A,20A,21-tetrol-3-one
- REICHSTEIN'S EPI ''E''
- REICHSTEIN'S SUBSTANCE 'EPI' 'E'
- 20alpha-Dihydrocortisol
- 1719-79-5
- (8S,9S,10R,11S,13S,14S,17R)-17-[(1S)-1,2-dihydroxyethyl]-11,17-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
- NSC82878
- SCHEMBL2903879
- 20beta-Dihydrocortisol
- NSC-82878
- CHEMBL488842
- MLS002694142
- 20α-Dihydrocortisol
-
- Inchi： 1S/C21H32O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-18,22,24-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
- InChI Key： AWWCEQOCFFQUKS-FJWDNACWSA-N
- SMILES： O[C@]1([C@H](CO)O)CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3[C@H](C[C@@]21C)O)=O
Computed Properties
- Exact Mass: 364.22500
- Monoisotopic Mass: 364.225
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 26
- Rotatable Bond Count: 2
- Complexity: 644
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 0.8
- Topological Polar Surface Area: 98?2
Experimental Properties
- Density: 1.29
- Boiling Point: 586.6oC at 760 mmHg
- Flash Point: 322.6 oC
- Refractive Index: 1.602
- PSA: 94.83000
- LogP: 1.86150
20α-Dihydrocortisol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D459580-25mg |
20α-Dihydrocortisol |
1719-79-5 | 25mg |
$ 207.00 | 2023-04-17 | ||
| TRC | D459580-100mg |
20α-Dihydrocortisol |
1719-79-5 | 100mg |
$ 800.00 | 2023-09-07 | ||
| TRC | D459580-250mg |
20α-Dihydrocortisol |
1719-79-5 | 250mg |
$ 1642.00 | 2023-04-17 |
20α-Dihydrocortisol Related Literature
-
Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
-
Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
-
Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
-
Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
Additional information on 20α-Dihydrocortisol
20α-Dihydrocortisol (CAS No. 1719-79-5): A Comprehensive Overview of Its Biochemical Significance and Recent Research Applications
20α-Dihydrocortisol, with the chemical formula C21H30O5 and CAS number 1719-79-5, is a naturally occurring corticosteroid hormone that belongs to the class of glucocorticoids. This compound is primarily synthesized in the adrenal cortex and plays a crucial role in regulating various physiological processes, including stress response, metabolism, and immune function. Over the years, extensive research has been conducted to elucidate its biochemical mechanisms and explore its potential therapeutic applications.
The structure of 20α-Dihydrocortisol features a cortisol backbone with a hydroxyl group at the 20th carbon position, which distinguishes it from other corticosteroids. This structural modification imparts unique pharmacological properties, making it a subject of interest in both academic research and pharmaceutical development. The compound's ability to interact with glucocorticoid receptors (GR) has been extensively studied, revealing its potential as an anti-inflammatory and immunosuppressive agent.
In recent years, advancements in biochemical analysis have allowed researchers to gain deeper insights into the molecular mechanisms of 20α-Dihydrocortisol. Studies have demonstrated that this compound exhibits a high affinity for GR, leading to significant downregulation of pro-inflammatory cytokine expression. This property has been particularly relevant in the context of chronic inflammatory diseases, where targeted suppression of inflammation is crucial for disease management.
One of the most compelling areas of research involving 20α-Dihydrocortisol is its potential application in treating autoimmune disorders. Autoimmune conditions such as rheumatoid arthritis and multiple sclerosis are characterized by aberrant immune responses that lead to tissue damage and chronic inflammation. Preclinical studies have shown that 20α-Dihydrocortisol can modulate immune cell activity by inhibiting the production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings have prompted further investigation into its therapeutic efficacy in human clinical trials.
The pharmacokinetic profile of 20α-Dihydrocortisol has also been a focus of interest. Unlike synthetic corticosteroids such as prednisone, which exhibit prolonged half-lives and potential side effects, natural analogs like 20α-Dihydrocortisol are expected to have a more rapid clearance from the body. This characteristic could minimize long-term adverse effects and improve patient compliance in therapeutic regimens.
In addition to its immunomodulatory properties, 20α-Dihydrocortisol has shown promise in regulating metabolic processes. Research indicates that this compound can influence glucose homeostasis by enhancing insulin sensitivity in peripheral tissues. This effect is particularly relevant in the context of type 2 diabetes mellitus, where improving insulin responsiveness is a key therapeutic goal.
The synthesis of 20α-Dihydrocortisol has also been optimized through modern biotechnological approaches. Recombinant DNA technology has enabled the production of this compound in microbial systems, offering a scalable and cost-effective method for pharmaceutical manufacturing. Such advancements have not only improved accessibility but also facilitated further research into its biological activities.
Ethical considerations have also been addressed in the development and use of 20α-Dihydrocortisol. Given its natural origin and relatively low toxicity profile, this compound presents a favorable alternative to synthetic corticosteroids for certain clinical applications. However, ongoing research is necessary to fully understand its long-term effects and potential interactions with other medications.
The future direction of research on 20α-Dihydrocortisol includes exploring its role in neuroprotection and cognitive function. Preliminary studies suggest that this compound may have neurotrophic effects, potentially benefiting conditions such as Alzheimer's disease and Parkinson's disease. These findings warrant further investigation to determine whether 20α-Dihydrocortisol can be developed into a novel therapeutic strategy for neurological disorders.
In conclusion, 20α-Dihydrocortisol (CAS No. 1719-79-5) represents a significant advancement in corticosteroid research due to its unique biochemical properties and therapeutic potential. The combination of preclinical evidence and ongoing clinical trials highlights its promise as an effective treatment for various inflammatory and metabolic disorders. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in modern medicine.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier